Cevimeline hydrochloride 30 MG Oral Capsule — RxCUI 309140
RxNorm drug concept · Semantic clinical drug
RxCUI 309140
Semantic clinical drug · SCD
● Current RxNorm concept 19 FDA products
34 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI309140
Official nameCevimeline hydrochloride 30 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known ascevimeline HCl 30 MG Oral Capsule
FDA products mapped19
Package NDCs mapped34
Reported Medicaid activity (SDUD)14,121 prescriptions · 40 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Cevimeline: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It treats dry mouth symptoms in people with Sjögren’s Syndrome. It comes as a capsule you take by mouth.
- You take the capsule three times a day. Food slows how fast it is absorbed, so ask me about timing. Don’t take more than prescribed, since higher amounts haven’t been shown to help...
- Sweating is the most common, and nausea, a runny nose and diarrhea can happen too. You may also notice extra saliva. Let your doctor know if they bother you.
- Call if you have chest pain, heart rhythm changes, breathing trouble or vision changes. Be careful driving at night, since vision and depth perception can be affected.
🕸️ Concept Web — How Cevimeline hydrochloride 30 MG Oral Capsule Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Cevimeline hydrochloride 30 MG Oral Capsule
RxCUI 309140 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Cevimeline
44281IN -
Cevimeline hydrochloride
260036PIN
-
Cevimeline
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Evoxac
261514BN
-
Evoxac
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Cevimeline Oral Capsule
378855SCDF -
Cevimeline hydrochloride Oral Capsule
2648307SCDFP -
Cevimeline Oral Product
1161241SCDG -
Cevimeline Pill
1161242SCDG -
Cevimeline hydrochloride Oral Product
2662955SCDGP -
Cevimeline hydrochloride Pill
2662390SCDGP -
Cevimeline Oral Capsule [Evoxac]
366528SBDF -
Cevimeline hydrochloride Oral Capsule [Evoxac]
2657808SBDFP - +5 more in this family
-
Cevimeline Oral Capsule
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Cevimeline hydrochloride 30 MG
2606838SCDC -
Cevimeline hydrochloride 30 MG Oral Capsule [Evoxac]
261361SBD -
Cevimeline hydrochloride 30 MG [Evoxac]
2606840SBDC
-
Cevimeline hydrochloride 30 MG
Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Cevimeline hydrochloride 30 MG
SCDC · 2606838 -
Cevimeline Oral Capsule
SCDF · 378855 -
Cevimeline hydrochloride Oral Capsule
SCDFP · 2648307 -
Cevimeline Oral Product
SCDG · 1161241 -
Cevimeline Pill
SCDG · 1161242 -
Cevimeline hydrochloride Oral Product
SCDGP · 2662955 -
Cevimeline hydrochloride Pill
SCDGP · 2662390
Brand-Name Concepts
-
Cevimeline hydrochloride 30 MG Oral Capsule [Evoxac]
SBD · 261361 -
Cevimeline hydrochloride 30 MG [Evoxac]
SBDC · 2606840 -
Cevimeline Oral Capsule [Evoxac]
SBDF · 366528 -
Cevimeline hydrochloride Oral Capsule [Evoxac]
SBDFP · 2657808 -
Evoxac Oral Product
SBDG · 1171819 -
Evoxac Pill
SBDG · 1171820 -
Evoxac
BN · 261514
📦 FDA Products & Package NDCs
19 products · 34 package NDCs
34 package NDCs map to RxCUI 309140 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00054-0334-25 | 100 CAPSULE in 1 BOTTLE (0054-0334-25) | Cevimeline Hydrochloride | Hikma Pharmaceuticals USA Inc. | 2013-07-08 |
| 00713-0883-01 | 100 CAPSULE in 1 BOTTLE, PLASTIC (0713-0883-01) | Evoxac | Cosette Pharmaceuticals, Inc. | 2022-09-01 |
| 00713-0937-01 | 100 CAPSULE in 1 BOTTLE, PLASTIC (0713-0937-01) | cevimeline hydrochloride | Cosette Pharmaceuticals, Inc. | 2023-01-03 |
| 16571-0657-10 | 100 CAPSULE in 1 BOTTLE (16571-657-10) | Cevimeline Hydrochloride | Rising Pharma Holdings, Inc. | 2014-06-17 |
| 33342-0216-11 | 100 CAPSULE in 1 BOTTLE (33342-216-11) | Cevimeline Hydrochloride | Macleods Pharmaceuticals Limited | 2024-10-20 |
| 40032-0999-01 | 100 CAPSULE in 1 BOTTLE (40032-999-01) | cevimeline hydrochloride | Novel Laboratories, Inc. | 2016-12-30 |
| 40032-0999-03 | 30 CAPSULE in 1 BOTTLE (40032-999-03) | cevimeline hydrochloride | Novel Laboratories, Inc. | 2016-12-30 |
| 40032-0999-05 | 500 CAPSULE in 1 BOTTLE (40032-999-05) | cevimeline hydrochloride | Novel Laboratories, Inc. | 2016-12-30 |
| 59651-0422-01 | 100 CAPSULE in 1 BOTTLE (59651-422-01) | Cevimeline Hydrochloride | Aurobindo Pharma Limited | 2023-04-18 |
| 59651-0422-05 | 500 CAPSULE in 1 BOTTLE (59651-422-05) | Cevimeline Hydrochloride | Aurobindo Pharma Limited | 2023-04-18 |
| 63304-0479-01 | 100 CAPSULE in 1 BOTTLE (63304-479-01) | Cevimeline | Sun Pharmaceutical Industries, Inc. | 2016-03-10 |
| 63629-9863-01 | 30 CAPSULE in 1 BOTTLE (63629-9863-1) | Cevimeline Hydrochloride | Bryant Ranch Prepack | 2023-11-30 |
| 63629-9863-02 | 60 CAPSULE in 1 BOTTLE (63629-9863-2) | Cevimeline Hydrochloride | Bryant Ranch Prepack | 2024-09-05 |
| 63629-9863-03 | 90 CAPSULE in 1 BOTTLE (63629-9863-3) | Cevimeline Hydrochloride | Bryant Ranch Prepack | 2024-09-05 |
| 69452-0316-20 | 100 CAPSULE in 1 BOTTLE (69452-316-20) | CEVIMELINE | Bionpharma Inc | 2024-01-17 |
| 70771-1982-01 | 100 CAPSULE in 1 BOTTLE (70771-1982-1) | Cevimeline Hydrochloride | Zydus Lifesciences Limited | 2026-04-15 |
| 71335-2264-01 | 30 CAPSULE in 1 BOTTLE (71335-2264-1) | Cevimeline Hydrochloride | Bryant Ranch Prepack | 2023-10-27 |
| 71335-2264-02 | 60 CAPSULE in 1 BOTTLE (71335-2264-2) | Cevimeline Hydrochloride | Bryant Ranch Prepack | 2023-10-27 |
| 71335-2264-03 | 90 CAPSULE in 1 BOTTLE (71335-2264-3) | Cevimeline Hydrochloride | Bryant Ranch Prepack | 2023-10-27 |
| 71335-2326-01 | 30 CAPSULE in 1 BOTTLE, PLASTIC (71335-2326-1) | CEVIMELINE HYDROCHLORIDE | Bryant Ranch Prepack | 2024-01-08 |
| 71335-2326-02 | 60 CAPSULE in 1 BOTTLE, PLASTIC (71335-2326-2) | CEVIMELINE HYDROCHLORIDE | Bryant Ranch Prepack | 2024-01-08 |
| 71335-2326-03 | 90 CAPSULE in 1 BOTTLE, PLASTIC (71335-2326-3) | CEVIMELINE HYDROCHLORIDE | Bryant Ranch Prepack | 2024-01-08 |
| 72162-2563-01 | 100 CAPSULE in 1 BOTTLE (72162-2563-1) | Cevimeline Hydrochloride | Bryant Ranch Prepack | 2025-11-04 |
| 72578-0208-01 | 100 CAPSULE in 1 BOTTLE (72578-208-01) | Cevimeline Hydrochloride | Viona Pharmaceuticals Inc | 2026-04-15 |
| 72789-0457-01 | 100 CAPSULE in 1 BOTTLE, PLASTIC (72789-457-01) | CEVIMELINE HYDROCHLORIDE | PD-Rx Pharmaceuticals, Inc. | 2024-12-30 |
| 72789-0457-30 | 30 CAPSULE in 1 BOTTLE, PLASTIC (72789-457-30) | CEVIMELINE HYDROCHLORIDE | PD-Rx Pharmaceuticals, Inc. | 2024-12-30 |
| 72888-0118-00 | 1000 CAPSULE in 1 BOTTLE, PLASTIC (72888-118-00) | CEVIMELINE HYDROCHLORIDE | Advagen Pharma Ltd | 2023-05-03 |
| 72888-0118-01 | 100 CAPSULE in 1 BOTTLE, PLASTIC (72888-118-01) | CEVIMELINE HYDROCHLORIDE | Advagen Pharma Ltd | 2023-05-03 |
| 72888-0118-05 | 500 CAPSULE in 1 BOTTLE, PLASTIC (72888-118-05) | CEVIMELINE HYDROCHLORIDE | Advagen Pharma Ltd | 2023-05-03 |
| 72888-0118-30 | 30 CAPSULE in 1 BOTTLE, PLASTIC (72888-118-30) | CEVIMELINE HYDROCHLORIDE | Advagen Pharma Ltd | 2023-05-03 |
| 87063-0180-01 | 100 CAPSULE in 1 BOTTLE (87063-180-01) | Cevimeline Hydrochloride | ASCLEMED USA INC. | 2026-05-18 |
| 87063-0180-30 | 30 CAPSULE in 1 BOTTLE (87063-180-30) | Cevimeline Hydrochloride | ASCLEMED USA INC. | 2026-05-18 |
| 87063-0180-60 | 60 CAPSULE in 1 BOTTLE (87063-180-60) | Cevimeline Hydrochloride | ASCLEMED USA INC. | 2026-05-18 |
| 87063-0180-90 | 90 CAPSULE in 1 BOTTLE (87063-180-90) | Cevimeline Hydrochloride | ASCLEMED USA INC. | 2026-05-18 |
Observed labelers:
Bryant Ranch Prepack (10) ·
Advagen Pharma Ltd (4) ·
ASCLEMED USA INC. (4) ·
Novel Laboratories, Inc. (3) ·
Aurobindo Pharma Limited (2) ·
Cosette Pharmaceuticals, Inc. (2)
· +9 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
💲 Pricing (NADAC)
NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.6871
Range $0.6871–$8.5909
· middle 50% $0.6871–$0.6871
· 10 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.